Extreme hypocalcaemia and hyperparathyroidism following denosumab. Is this drug safe in chronic kidney disease?
Hipocalcemia e hiperparatiroidismo extremos tras denosumab. ¿Es seguro este fármaco en la enfermedad renal crónica?
Read
18892
Timeswas read the article
3323
Total PDF
15569
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 260 | 210 | 470 |
| 2025 5 | 282 | 39 | 321 |
| 2025 4 | 167 | 21 | 188 |
| 2025 3 | 225 | 69 | 294 |
| 2025 2 | 208 | 34 | 242 |
| 2025 1 | 177 | 40 | 217 |
| 2024 12 | 130 | 42 | 172 |
| 2024 11 | 126 | 56 | 182 |
| 2024 10 | 114 | 45 | 159 |
| 2024 9 | 110 | 39 | 149 |
| 2024 8 | 121 | 66 | 187 |
| 2024 7 | 114 | 38 | 152 |
| 2024 6 | 130 | 44 | 174 |
| 2024 5 | 137 | 45 | 182 |
| 2024 4 | 122 | 33 | 155 |
| 2024 3 | 108 | 32 | 140 |
| 2024 2 | 105 | 32 | 137 |
| 2024 1 | 87 | 28 | 115 |
| 2023 12 | 76 | 27 | 103 |
| 2023 11 | 125 | 41 | 166 |
| 2023 10 | 101 | 40 | 141 |
| 2023 9 | 85 | 35 | 120 |
| 2023 8 | 84 | 33 | 117 |
| 2023 7 | 145 | 23 | 168 |
| 2023 6 | 185 | 20 | 205 |
| 2023 5 | 183 | 38 | 221 |
| 2023 4 | 110 | 14 | 124 |
| 2023 3 | 126 | 36 | 162 |
| 2023 2 | 84 | 23 | 107 |
| 2023 1 | 107 | 41 | 148 |
| 2022 12 | 92 | 38 | 130 |
| 2022 11 | 89 | 28 | 117 |
| 2022 10 | 124 | 52 | 176 |
| 2022 9 | 92 | 44 | 136 |
| 2022 8 | 80 | 44 | 124 |
| 2022 7 | 75 | 44 | 119 |
| 2022 6 | 70 | 37 | 107 |
| 2022 5 | 74 | 34 | 108 |
| 2022 4 | 95 | 56 | 151 |
| 2022 3 | 71 | 44 | 115 |
| 2022 2 | 85 | 40 | 125 |
| 2022 1 | 123 | 37 | 160 |
| 2021 12 | 94 | 48 | 142 |
| 2021 11 | 112 | 40 | 152 |
| 2021 10 | 199 | 51 | 250 |
| 2021 9 | 124 | 44 | 168 |
| 2021 8 | 96 | 36 | 132 |
| 2021 7 | 131 | 43 | 174 |
| 2021 6 | 116 | 39 | 155 |
| 2021 5 | 79 | 43 | 122 |
| 2021 4 | 224 | 49 | 273 |
| 2021 3 | 158 | 43 | 201 |
| 2021 2 | 147 | 16 | 163 |
| 2021 1 | 120 | 29 | 149 |
| 2020 12 | 114 | 26 | 140 |
| 2020 11 | 120 | 15 | 135 |
| 2020 10 | 74 | 19 | 93 |
| 2020 9 | 126 | 19 | 145 |
| 2020 8 | 87 | 22 | 109 |
| 2020 7 | 125 | 18 | 143 |
| 2020 6 | 102 | 44 | 146 |
| 2020 5 | 144 | 24 | 168 |
| 2020 4 | 94 | 19 | 113 |
| 2020 3 | 98 | 28 | 126 |
| 2020 2 | 146 | 26 | 172 |
| 2020 1 | 130 | 25 | 155 |
| 2019 12 | 157 | 40 | 197 |
| 2019 11 | 165 | 29 | 194 |
| 2019 10 | 138 | 27 | 165 |
| 2019 9 | 172 | 18 | 190 |
| 2019 8 | 156 | 21 | 177 |
| 2019 7 | 168 | 25 | 193 |
| 2019 6 | 133 | 22 | 155 |
| 2019 5 | 137 | 30 | 167 |
| 2019 4 | 166 | 41 | 207 |
| 2019 3 | 89 | 24 | 113 |
| 2019 2 | 63 | 22 | 85 |
| 2019 1 | 77 | 29 | 106 |
| 2018 12 | 138 | 52 | 190 |
| 2018 11 | 156 | 17 | 173 |
| 2018 10 | 132 | 16 | 148 |
| 2018 9 | 146 | 15 | 161 |
| 2018 8 | 101 | 17 | 118 |
| 2018 7 | 106 | 15 | 121 |
| 2018 6 | 100 | 21 | 121 |
| 2018 5 | 107 | 18 | 125 |
| 2018 4 | 132 | 7 | 139 |
| 2018 3 | 107 | 8 | 115 |
| 2018 2 | 94 | 6 | 100 |
| 2018 1 | 105 | 5 | 110 |
| 2017 12 | 90 | 9 | 99 |
| 2017 11 | 115 | 11 | 126 |
| 2017 10 | 101 | 11 | 112 |
| 2017 9 | 94 | 7 | 101 |
| 2017 8 | 121 | 13 | 134 |
| 2017 7 | 129 | 16 | 145 |
| 2017 6 | 122 | 17 | 139 |
| 2017 5 | 128 | 14 | 142 |
| 2017 4 | 136 | 40 | 176 |
| 2017 3 | 97 | 19 | 116 |
| 2017 2 | 114 | 16 | 130 |
| 2017 1 | 102 | 13 | 115 |
| 2016 12 | 115 | 10 | 125 |
| 2016 11 | 137 | 9 | 146 |
| 2016 10 | 198 | 16 | 214 |
| 2016 9 | 234 | 8 | 242 |
| 2016 8 | 236 | 11 | 247 |
| 2016 7 | 278 | 10 | 288 |
| 2016 6 | 186 | 0 | 186 |
| 2016 5 | 199 | 0 | 199 |
| 2016 4 | 144 | 0 | 144 |
| 2016 3 | 118 | 0 | 118 |
| 2016 2 | 149 | 0 | 149 |
| 2016 1 | 138 | 0 | 138 |
| 2015 12 | 136 | 0 | 136 |
| 2015 11 | 114 | 0 | 114 |
| 2015 10 | 122 | 0 | 122 |
| 2015 9 | 116 | 0 | 116 |
| 2015 8 | 93 | 0 | 93 |
| 2015 7 | 125 | 0 | 125 |
| 2015 6 | 74 | 0 | 74 |
| 2015 5 | 86 | 0 | 86 |
| 2015 4 | 13 | 0 | 13 |
Show all
